Company Profile
Catalent Stock Price, News & Analysis
- Ticker:
- CTLT
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for CTLT.
Company overview
Business overview
Catalent was a pharmaceutical development and delivery company that supported drug formulation, manufacturing, and packaging before being acquired and taken private. It played a major role in outsourced pharma and biotech operations.
Geographic Base and Sector Classification
Catalent was headquartered in the United States and traded on NYSE before the acquisition. It sat in contract development and manufacturing rather than therapeutics.
Business Model Characteristics
The company generated revenue from manufacturing, development, fill-finish, and delivery services for pharma customers. Investors historically watched outsourcing demand, production utilization, and margin recovery.
Position Within the Biotechnology Landscape
Catalent was a major infrastructure name for biotech and pharma, especially in manufacturing and delivery services. Because it has been acquired, it now belongs to historical sector infrastructure rather than the live public-company universe.
Future catalysts
Catalent’s near-term catalysts are still transaction-related, with integration, divestiture, and site-rationalization milestones doing most of the work. That matters because demand only becomes valuable if the company can actually deliver at scale. Any improvement in supply or capacity can change how investors think about the next leg of the revenue curve.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Catalent do?
Catalent was a pharmaceutical development and delivery company that supported drug formulation, manufacturing, and packaging before being acquired and taken private. It played a major role in outsourced pharma and biotech operations.
On which exchange is CTLT stock listed?
Catalent (CTLT) is associated with NYSE, United States, Biopharma.
What is Catalent?
Catalent’s near-term catalysts are still transaction-related, with integration, divestiture, and site-rationalization milestones doing most of the work.
Which conditions is Catalent targeting with Catalent?
Catalent’s near-term catalysts are still transaction-related, with integration, divestiture, and site-rationalization milestones doing most of the work.
How does Catalent describe recent progress with Catalent?
Catalent’s near-term catalysts are still transaction-related, with integration, divestiture, and site-rationalization milestones doing most of the work.
What is That?
Catalent was a pharmaceutical development and delivery company that supported drug formulation, manufacturing, and packaging before being acquired and taken private.
What should investors watch for with That?
That matters because demand only becomes valuable if the company can actually deliver at scale.
What future catalysts are investors watching for Catalent?
Catalent’s near-term catalysts are still transaction-related, with integration, divestiture, and site-rationalization milestones doing most of the work. That matters because demand only becomes valuable if the company can actually deliver at scale. Any improvement in supply or capacity can change how investors think about the next leg of the revenue curve.